Advances in the understanding and management of vitiligo

Vitiligo is a chronic pigmentary disorder with a profound psychosocial impact that is often underestimated by both the general population and physicians. Prof Dr Nanja van Geel, dermatologist at Ghent University Hospital discusses some recent scientific advances and clinical developments that were highlighted during the EADV Congress.

An important step in advancing care has been the establishment of international collaborations, such as the Vitiligo Task Force, which unites dermatology experts and patients from across continents. This group has recently published expert-based recommendations. These represent the first global guidelines for vitiligo management, complementing previously available national guidelines. The inclusion of an algorithm offers practical support for dermatologists, facilitating standardised decision-making in clinical practice. Central to these recommendations is the assessment of disease activity, which is a key determinant of therapeutic choice. Clinical signs such as confetti-like depigmentation are reliable indicators of disease progression and may prompt more aggressive treatment approaches.

The Task Force is also addressing complex clinical situations, such as patients presenting with both vitiligo and melasma, where contrasting pigmentary disorders complicate therapeutic decision-making. Consensus statements and practical recommendations aim to provide guidance in such scenarios, highlighting the value of collaborative expertise and patient input.

Therapeutic innovation is also reshaping the field. The approval of topical ruxolitinib cream as the first targeted therapy for vitiligo represents a milestone. Ongoing clinical trials are expected to expand treatment options further, and current research suggests that novel systemic and topical agents will soon broaden the therapeutic landscape.

In summary, the management of vitiligo is entering a transformative era. Global collaboration has enabled the development of international guidelines that support both expert and general dermatologists in daily practice, while new therapies offer effective and personalized options for patients. Together, these developments mark significant progress in the recognition and treatment of this impactful disease.